Granuloma Annulare, Scalp Necrosis, and Ischemic Optic Neuropathy From Giant Cell Arteritis After Varicella-Zoster Virus Vaccination

Clinical Correspondence Section Editors: Robert Avery, DO Karl C. Golnik, MD Caroline Froment, MD, PhD An-Gour Wang, MD Granuloma Annulare, Scalp Necrosis, and Ischemic Optic Neuropathy From Giant Cell Arteritis After VaricellaZoster Virus Vaccination Prem Nichani, MSc, Jonathan A. Micieli, MD G iant cell arteritis (GCA) is a systemic vasculitis that begins with activation of dendritic cells in the arterial wall (1). This initiates a cascade that results in the recruitment of macrophages and T cells resulting in the classic histopathological features of GCA including disruption of the internal elastic lamina and luminal obstruction (2). The initial trigger for dendritic activation is not yet known; several infectious agents have been explored including varicella-zoster virus (VZV), but none have been proven (3). Epidemiological studies have not found a relationship between VZV or VZV vaccination and GCA (4,5). In this report, we describe the development of GCA complicated by unintentional weight loss, scalp necrosis, and ischemic optic neuropathy following a live-attenuated VZV vaccine. He was treated with oral valacyclovir without improvement. His scalp pain significantly worsened, and 6 months after vaccination, he started to have progressive breakdown of the skin in the center of his forehead (Fig. 2A–D). Eight months after vaccination, he developed sudden bilateral vision loss and was referred to neuro-ophthalmology. He had a visual acuity of hand motions in the right eye and no light perception in the left eye. Dilated fundus examination revealed right optic disc edema secondary to anterior ischemic optic neuropathy and signs of a left central retinal artery occlusion (Fig. 3). He also had very firm and nodular temporal arteries (Fig. 2D). Repeat ESR was 108 mm/hour, and CRP was 110 mg/L. He was treated with 5 days of intravenous methylprednisolone followed by oral prednisone. CASE REPORT An 88-year-old Italian man with hypertension, type 2 diabetes, dyslipidemia, coronary artery disease, and early dementia received a live-attenuated shingles vaccine, Zostavax. A few days later, he developed generalized pinkcolored patches on his back and trunks diagnosed as generalized granuloma annulare (GA; Fig. 1). Skin biopsy showed palisading granulomatous inflammation around necrobiotic collagen fibers. He was treated with multiple topical steroid creams and a 1-week oral course of prednisone resulting in temporary improvement. Three weeks after vaccination, he developed progressively worsening fatigue and decreasing appetite with unintentional weight loss of 50 pounds over the next 3 months. Two months after vaccination, he developed newonset scalp pain and worsening GA. Five months after vaccination, he underwent investigations that included a hemoglobin of 91g/L, platelet count of 311 · 109/L, erythrocyte sedimentation rate (ESR) of 80 mm/hour, and C-reactive protein (CRP) of 44 mg/L (normal , 11 mg/L). Faculty of Medicine (PN), University of Toronto, Toronto, Canada; Department of Ophthalmology and Vision Sciences (JAM), University of Toronto, Toronto, Canada; and Division of Neurology (JAM), Department of Medicine, University of Toronto, Toronto, Canada. The authors report no conflicts of interest. Address correspondence to Jonathan A. Micieli, Kensington Vision and Research Centre, 340 College Street, Suite 501, Toronto, ON M5T 3A9, Canada; E-mail: [e-mail] Nichani and Micieli: J Neuro-Ophthalmol 2021; 41: e145-e148 FIG. 1. A few days after the Zostavax vaccine, he developed pink- to purple-colored coalesced papules on the back due to generalized granuloma annulare. e145 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. Clinical Correspondence FIG. 2. External images demonstrating progressive scalp necrosis that began 6 months after vaccination. Images (A–D) are before treatment with steroids and images (E, F) are 1 and 6 months after steroid treatment, respectively. Subsequent biopsy of the left temporal artery confirmed the diagnosis of GCA; viral polymerase chain reaction (PCR) was performed on the temporal artery biopsy, and VZV was not detected (Fig. 4). The patient was continued on oral prednisone under the care of rheumatology, and his inflammatory markers continued to decline. His scalp significantly improved, and he had no necrotic visible areas 4 months after steroid treatment (Fig. 2E–F). His visual acuity mildly improved to 20/400 in both eyes 6 months after vision loss. DISCUSSION It has long been hypothesized that an infectious agent such as VZV may be the cause for a granulomatous arteritis such as GCA (3). Large population-based studies have not found a relationship between VZV reactivation and GCA incidence (4,5). However, some studies have detected VZV in a high proportion of positive and negative temporal artery biopsies (6,7), but this has not been replicated other studies on this topic (8,9). As recent reviews have highlighted (10,11), it is possible that 1) VZV is an innocent bystander in GCA cases because more people carry the virus, 2) VZV may trigger GCA, or 3) VZV actually causes GCA. This case supports the second hypothesis given the clear temporal relationship to the live-attenuated VZV vaccine and less likely the third hypothesis since his symptoms, in particular the scalp necrosis, improved considerably on high-dose corticosteroids alone, and he did not have any clear clinical manifestations of VZV. VZV was also not detectable in the temporal artery biopsy specimen by PCR. Previous studies have reported the development of GCA after vaccination. Soriano et al (12) reported 10 cases of previously healthy individuals that developed GCA or polymyalgia rheumatica (PMR) within 3 months of influenza vaccination. Additional 10 cases of GCA/PMR after vaccination have also been reported in the literature spanning over 30 years, indicating that this phenomenon is not a result of antigen specificity of the vaccine (13–21). A potential explanation is the interaction between vaccine antigens and specific HLA molecules such as HLADRB1*04 as a class II molecule on the antigen presenting cells results in an autoimmune reaction directed against the FIG. 3. Fundus photographs demonstrating right optic disc edema in the right eye (OD) from an anterior ischemic optic neuropathy. There was limited filling of the retinal arterioles in the left eye (OS) due to a central retinal artery occlusion. e146 Nichani and Micieli: J Neuro-Ophthalmol 2021; 41: e145-e148 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. Clinical Correspondence FIG. 4. Hematoxylin and eosin (A) and Gomori trichrome (B) stain of the temporal artery biopsy specimen demonstrating an influx of mononuclear inflammatory cells with associated breakdown of the internal elastic lamina (red arrows) and influx of mononuclear cells in the adventitia (black arrows). The yellow star indicates significant cellular intimal thickening as well as disruption of the internal elastic lamina and inflammatory cells. temporal artery and clinical manifestations of GCA (17). Vaccine adjuvants may also play a role in the induction of postvaccine adverse events including vasculitis (22). This also seems to mainly occur in genetically susceptible individuals carrying specific HLA-DRB1 genes (22). Another unique aspect of this case is the relationship between GA and GCA. We were able to retrieve 4 previous cases in the literature where this relationship existed (23– 26). The average age of these patients was 76.5 and 3 patients developed GA first, between 1 month and 1 year before developing symptoms of GCA. Only one case was complicated by loss of vision (23) and both conditions responded well to steroids (24). GA and GCA share several common features including a common histopathological pattern of granulomatous inflammation, giant cells, and loss of elastic fibers and response to corticosteroids. However, GA is benign condition that is much more common than GCA and has been reported to be incited by trauma, infections, malignancy, and drugs. Vasculitis is also not believed to play a major role as evidenced by dermatopathology specimens (27). Nonetheless, the close temporal association in our case and those in the literature warrant consideration of GCA in patients presenting with new GA, especially if there are constitutional symptoms. In conclusion, GCA may occur in close temporal relationship to vaccines, including the live-attenuated VZV vaccine. Given the complicated relationship between VZV and GCA, symptoms that develop after the VZV vaccine may be misattributed to the virus itself. Understanding the potential for developing vasculitis after vaccines, such as that directed against VZV, would allow for earlier detection and the prevention of serious complications such as scalp necrosis and permanent vision loss. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. REFERENCES 1. Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;37:50–57. 2. Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol. 2012;32:259–265. 3. Helweg-Larsen J, Tarp B, Obel N, Baslund B. No evidence of parvovirus B19, Chlamydia pneumoniae or human herpes virus Nichani and Micieli: J Neuro-Ophthalmol 2021; 41: e145-e148 14. 15. 16. infection in temporal artery biopsies in patients with giant cell arteritis. Rheumatology (Oxford). 2002;41:445–449. Ing EB, Ing R, Liu X, Zhang A, Torun N, Sey M, Pagnoux C. Does herpes zoster predispose to giant cell arteritis: a geoepidemiologic study. Clin Ophthalmol. 2018;12:113–118. Lotan I, Steiner I. Giant cell arteritis following varicella zoster vaccination. J Neurol Sci. 2017;375:158–159. Gilden D, White T, Khmeleva N, Heintzman A, Choe A, Boyer P, Grose C, Carpenter JE, Rempel A, Bos N, Kandasmy B, LearKaul K, Holmes DB, Bennett JL, Cohrs RJ, Mahalingam R, Mandava N, Eberhart CG, Bockelman B, Poppiti RJ, Tamhankar MA, Fogt F, Amato M, Wood E, Durairaj V, Rasmussen S, Petursdottir V, Pollak L, Mendlovic S, Chatelain D, Keyvani K, Brueck W, Nagel MA. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology. 2015;85:1914–1915. Nagel MA, White T, Khmeleva N, Rempel A, Boyer PJ, Bennett JL, Haller A, Lear-Kaul K, Kandasmy B, Amato M, Wood E, Durairaj V, Fogt F, Tamhankar MA, Grossniklaus HE, Poppiti RJ, Bockelman B, Keyvani K, Pollak L, Mendlovic S, Fowkes M, Eberhart CG, Buttmann M, Toyka KV, Meyer-ter-Vhen T, Petursdottir V, Gilden D. Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis. JAMA Neurol. 2015;72:1281–1287. Buckingham EM, Foley MA, Grose C, Syed NA, Smith ME, Margolis TP, Thurtell MJ, Kardon R. Identification of herpes zoster–associated temporal arteritis among cases of giant cell arteritis. Am J Ophthalmol. 2018;187:51–60. Muratore F, Croci S, Tamagnini I, Zerbini A, Bellafiore S, Belloni L, Boiardi L, Bisagni A, Pipitone N, Parmeggiani M, Cavazza A, Salvarani C. No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. Semin Arthritis Rheum. 2017;47:235–240. Liao YJ, Kedar S. Should antiviral/anti-varicella zoster virus treatment be used in patients with giant cell arteritis? J Neuroophthalmol. 2019;39:134–141. Ostrowski RA, Metgud S, Tehrani R, Jay WM. Varicella zoster virus in giant cell arteritis: review of current medical literature. Neuroophthalmology. 2019;43:159–170. Soriano A, Verrecchia E, Marinaro A, Giovinale M, Fonnesu C, Landolfi R, Manna R. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21:153–157. Ghose MK, Shensa S, Lerner PI. Arteritis of the aged (giant cell arteritis) and fever of unexplained origin. Am J Med. 1976;60:429–436. Gerth HJ. Polymyalgia rheumatic and influenza vaccination. Dtsch Med Wochenschr. 1992;117:1259–1260. Brown MA, Bertouch JV. Rheumatic complications of influenza vaccination. Aust N Z J Med. 1994;24:572–573. Liozon E, Ittig R, Vogt N, Michel JP, Gold G. Polymyalgia rheumatica following influenza vaccination. J Am Geriatr Soc. 2000;48:1533–1534. e147 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. Clinical Correspondence 17. Perez C, Loza E, Tinture T. Giant cell arteritis after influenza vaccination. Arch Intern Med. 2000;160:2677. 18. Saadoun D, Cacoub P, Mahoux D, Sbai A, Piette JC. Postvaccine vasculitis: a report of three cases. Rev Med Intern. 2001;22:172–176. 19. Finsterer J, Artner C, Kladosek A, Kalchmayr R, Redtenbacher S. Cavernous sinus syndrome due to vaccination-induced giant cell arteritis. Arch Intern Med. 2001;161:1008–1009. 20. Marti J, Anton E. Polymyalgia rheumatica complicating influenza vaccination. J Am Geriatr Soc. 2004;52:1412. 21. Pou MA, Diaz-Torne C, Vidal S, Corchero C, Narvaez J, Nolla JM, Diaz-Lopez C. Development of autoimmune diseases after vaccination. J Clin Rheumatol. 2008;14:243–244. 22. Shoenfeld Y, Agmon-Levin N. “ASIA”—autoimmune/ inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4–8. e148 23. Torisu Y, Horai Y, Michitsuji T, Kawahara C, Mori T, Iwanaga N, Izumi Y, Kawakami A. Giant cell arteritis with generalized granuloma annulare. Intern Med. 2019;58:1173–1177. 24. Fukai K, Ishii M, Kobayashi H, Someda Y, Hamada T, Tsujino S. Generalized granuloma annulare in a patient with temporal arteritis: are these conditions associated? Clin Exp Dermatol. 1990;15:70–72. 25. Kluger N, Riviere S, Mura M, Guillot B, Girard C. Simultaneous occurrence of generalized granuloma annulare, anterior uveitis and giant cell arteritis: coincidental or not? Presse Med. 2012;41:548–549. 26. Yanez S, Val-Bernal JF, Pena-Sagredo JL. Granuloma annulare and giant cell arteritis. Clin Exp Rheumatol. 2008;3(suppl 49):S108–S110. 27. Güneş P, Göktay F, Mansur AT, Köker F, Erfan G. Collagen-elastic tissue changes and vascular involvement in granuloma annulare: a review of 35 cases. J Cutan Pathol. 2009;36:838–844. Nichani and Micieli: J Neuro-Ophthalmol 2021; 41: e145-e148 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited.